Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
   
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  SWAN Knowledge Base
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Pathways
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
World Alzheimer’s Report Estimates 35 Million Cases
22 September 2009 A new report commissioned by Alzheimer Disease International (ADI), the global umbrella organization of national Alzheimer associations, makes for easy and captivating reading while on call or while the computer is crunching experimental data. Whether toiling at the bedside or the bench, clinicians and researchers around the world rarely get the benefit of a sweeping big-picture view of what the disease they are fighting is up to around the globe, and how it will likely change in different regions of the world in coming decades.

The report came out on World Alzheimer’s Day on September 21, amidst publicity events aimed at raising Alzheimer disease awareness among the general publics and health and government communities around the world. The U.S. Alzheimer’s Association observed the day with a series of appearances on national media and a celebrities campaign, see In the News.

The World Alzheimer Report 2009 presents updated prevalence data for AD, estimating that about 35 million people are living with dementia now and that this number will nearly double every 20 years, to 65 million in 2030. This represents an increase over previous estimates (see related news story on Ferri et al., 2005; see also related news story on Rodriguez et al., 2008). One alarming aspect the report emphasizes is that a majority of people with dementia lives in low- and middle-income countries, where the proportionate increase in prevalence is predicted to outpace that in wealthy countries. The report further chronicles the impact of dementia on carers and societies around the world, and highlights some recent government initiatives to make Alzheimer disease a national priority, for example in England, France, Australia and South Korea. The report, along with supporting documentation and data files for those who wish to dig deeper, is freely available for download. —Gabrielle Strobel

 
Comments on Related News
Related News: Medical Foods—Fallback Option for Elusive AD Drug Status?

Comment by:  Suzanne Craft (Disclosure)
Submitted 14 October 2009 Posted 14 October 2009

As noted in this interesting article, I think the approach of supplying alternate forms of bioenergetic substrates to patients with Alzheimer disease is worth further exploration, and future studies must be designed and powered to test a differential APOE response, which we have observed in our own studies of insulin/energy-modulating agents. In the interest of full disclosure, as the article described, I received a small grant from Accera to conduct an acute dosing study of an MCT formulation in 2004; additionally, I also serve as a consultant for Accera, a fact that was not mentioned in the article.

View all comments by Suzanne Craft

Related News: Medical Foods—Fallback Option for Elusive AD Drug Status?

Comment by:  Steve Orndorff (Disclosure)
Submitted 28 October 2009 Posted 30 October 2009

The premise of this article is the notion that companies are using the medical food route as a “fallback” or backup strategy if their drug compound fails in the clinic. As I will discuss below, this premise is flawed. I wish to point out that this was never the intent for Axona (AC-1202). As I stated in the Tangled Neuron interview, Axona was originally intended to be a surrogate for testing our new therapeutic approach (ketone treatment for neuronal hypometabolism) in AD patients so the company could secure venture funding for its drug development platform. Based on our research, we found evidence that the dietary addition of ketones can delay and reduce the magnitude of cognitive dysfunction in patients with mild to moderate AD and can be an effective part of the dietary management of the disease. As a result, we concluded that the product could be appropriately marketed as a medical food. The company never filed an IND for Axona or intended to develop it as a drug. However, we did perform our clinical studies to pharmaceutical standards with industry and FDA-accepted...  Read more

View all comments by Steve Orndorff

Related News: Medical Foods—Fallback Option for Elusive AD Drug Status?

Comment by:  Frederic Calon
Submitted 12 November 2009 Posted 12 November 2009

I think it would have been a major advantage to get Ketasyn/AC1202 FDA-approved as a drug. Ketasyn/AC1202 could have then been used by health professionals and prescribed to the right persons. There is a strong rationale in using medium chain triglycerides (MTCs) as a source of ketone bodies to boost brain metabolism. It is likely that certain specific patients in “energy crisis”, such as very old persons for example, could benefit from MCTs. Unfortunately, the use of Ketasyn/AC1202 as a medical food will dilute its true therapeutic benefit.

In summary, I might be wrong but I think Ketasyn would have had more chance to achieve its full therapeutic potential as a drug than as a medical food.

View all comments by Frederic Calon

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2010 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad